Drug intelligence / Profile preview

RGI-Ab02

Development stage: Preclinical
Lead developer: REGiMMUNE
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

RGI-Ab02 is a novel monoclonal antibody being developed by REGiMMUNE Corporation as a checkpoint inhibitor for the treatment of solid tumors. It functions by binding to an inhibitory receptor expressed on CD8+ effector T cells and natural killer (NK) cells, thereby modulating immune checkpoint pathways to enhance anti-tumor activity. Currently in preclinical development, RGI-Ab02 is intended for use as a monotherapy or in combination with anti-PD-1 therapies and other internal antibody products.

Targets

KLRC1 (Killer cell lectin-like receptor subfamily C member 1)

Beyond the preview

Go deeper on RGI-Ab02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RGI-Ab02.

Explore the full profile